Therapeutic Response

EGFR somatic variants status confers therapeutic sensitivity to Afatinib in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Gilotrif (afatinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to afatinib for the first-line treatment of patients with metastatic non-small lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations, as detected by an FDA-approved test.
Giotrif (afatinib) [product monograph]. HC. Health Canada approved afatinib for the treatment of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor naïve patients with metastatic adenocarcinoma of the lung with activating EGFR mutation(s).